A Study of DB-1303 in Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and
tolerability of DB-1303 in subjects with advanced solid tumors that express HER2.